

Curriculum vitae and Bibliography

Date of preparation: June 15, 2016

A. GENERAL INFORMATION

1. Name **Gregory J. Riely, MD, PhD**
2. Office address: Memorial Sloan-Kettering Cancer Center
300 East 66th Street
New York, New York 10065
Office telephone: 646-888-4199
Office fax: 646-888-4262
3. Beeper: 5607
4. Email: rielyg@mskcc.org

B. EDUCATIONAL BACKGROUND

1.

| <i>Degree</i> | <i>Institution name and location</i> | <i>Dates attended</i> | <i>Year Awarded</i> |
|---------------|--|-----------------------|---------------------|
| BA | The Johns Hopkins University, Baltimore, Maryland | 1990-1994 | 1994 |
| PhD | Case Western Reserve University, Cleveland, Ohio | 1994-1999 | 1999 |
| MD | Case Western Reserve University Cleveland, Ohio | 1994-2001 | 2001 |

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

1. Post-doctoral training including residency/fellowship

| <i>Title</i> | <i>Institution name and location</i> | <i>Dates held</i> |
|--------------------|--|-------------------|
| Intern | New York Presbyterian Hospital – Weill Cornell Center, New York | 2001-2002 |
| Resident | New York Presbyterian Hospital – Weill Cornell Center, New York | 2002-2003 |
| Fellow | Memorial Hospital for Cancer & Allied Diseases | 2003-2006 |
| Fellow in Medicine | Weill Cornell Medical College, New York | 2003-2006 |

2. Academic positions (teaching and research)

| <i>Title</i> | <i>Institution name and location</i> | <i>Dates held</i> |
|-------------------------------|---|-------------------|
| Assistant Member (Level 1) | Memorial Sloan-Kettering Cancer Center, New York | 2007-2010 |
| Instructor | Weill Cornell Medical College, New York | 2007-2010 |
| Assistant Member | Memorial Sloan-Kettering Cancer Center, New York | 2010-2014 |
| Assistant Professor | Weill Cornell Medical College, New York | 2010-2014 |
| Associate Member | Memorial Sloan-Kettering Cancer Center, New York | 2014-Present |
| Associate Professor | Weill Cornell Medical College, New York | 2015-Present |

3. Hospital positions

| <i>Title</i> | <i>Institution name and location</i> | <i>Dates held</i> |
|---|---|-------------------|
| Assistant Attending Physician | Memorial Hospital for Cancer & Allied Diseases, New York, New York | 2007-2014 |
| Associate Chair, Clinical Trials Office, Department of Medicine | Memorial Hospital for Cancer & Allied Diseases, New York, New York | 10/2012-1/2013 |
| Associate Attending Physician | Memorial Hospital for Cancer & Allied Diseases, New York, New York | 2014-Present |
| Vice Chair, Clinical Trials Office, Department of Medicine | Memorial Hospital for Cancer & Allied Diseases, New York, New York | 1/2013-Present |

D. LICENSURE, BOARD CERTIFICATION

1. Licensure

| <u>State</u> | <u>Number</u> | <u>Date of issue</u> | <u>Date of expiration</u> |
|--------------|---------------|----------------------|---------------------------|
| New York | 228564 | 5/29/2003 | 5/31/2016 |

| | <u>Number</u> | <u>Date of issue</u> | <u>Date of expiration</u> |
|-------------|---------------|----------------------|---------------------------|
| <u>DEA:</u> | BR8357306 | 5/1/2006 | 4/30/2015 |
| <u>NPI:</u> | 1770648875 | 12/27/2006 | |

2. Board Certification

| Full Name of Board | Year passed | Year expires/d |
|-------------------------------------|-------------|----------------|
| American Board of Internal Medicine | | |
| Internal Medicine | 2004, 2014 | 2024 |
| Medical Oncology | 2006 | 2016 |

E. PROFESSIONAL MEMBERSHIPS (medical and scientific societies)

| <i>Member/officer</i> | <i>Name of Organization</i> | <i>Dates</i> |
|-----------------------|--|--------------|
| Member | American Society of Clinical Oncology | 1/1/2005 |
| Member | American Association of Cancer Research | 1/1/2006 |
| Member | Int. Assoc. for the Study of Lung Cancer | 4/1/2008 |

F. HONORS AND AWARDS

| Name of award | Date awarded |
|--|--------------|
| Dean's List, The Johns Hopkins University | 1991-1993 |
| Provost's Award for Undergraduate Research and Excellence, The Johns Hopkins University | 1993 |
| Fellowship in the Medical Scientist Training Program, Case Western Reserve University | 1994-2001 |
| AACR/ASCO Clinical Trials Workshop, Vail, Colorado | 2005 |
| ASCO Young Investigator Award | 2007 |

G. INSTITUTIONAL/HOSPITAL AFFILIATION

| | |
|-----------------------------------|--|
| Primary Hospital Affiliation: | Memorial Hospital for Cancer and Allied Diseases |
| Other Hospital Affiliations: | None |
| Other Institutional Affiliations: | Weill Cornell Medical College |

H. EMPLOYMENT STATUS

Name of Employer(s): Memorial Sloan-Kettering Cancer Center
Employment Status: full-time salaried

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND EFFORT

| | |
|---|--------------|
| 1. Teaching/Mentoring | |
| Medical Oncology/Hematology Fellow, responsible for teaching WCMC and MSKCC medical students and housestaff, | 2003- 2006 |
| Assistant Attending Physician, responsible for teaching MSKCC and WCMC medical students, housestaff, and fellows | 2007-present |
| Lecture: Solid Tumor/Hematologic Oncology Grand Rounds, "Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC" | 10/16/2006 |
| Lecture: Solid Tumor/Hematologic Oncology Grand Rounds, "KRAS mutations in non-small cell lung cancer" | 11/20/2007 |
| Lecture: Medical Oncology Fellows: EGFR and Lung Cancer | 2/13/2007 |

| | |
|--|-----------------|
| MSKCC Resident Morning Report: Non-Small Cell Lung Cancer | 2/22/2007 |
| Case Conference: Medical Oncology Fellows: NSCLC | 4/2/2007 |
| Case Conference: Medical Oncology Fellows: Thymic Malignancies | 4/9/2007 |
| Landmark Clinical Trials Journal Club – Medical Oncology Fellows | 7/14/2008 |
| Lecture: MSKCC Resident Noon Conference | 7/17/2008 |
| MSKCC Resident Morning Report: Non-Small Cell Lung Cancer | 8/5/2008 |
| MSKCC Resident Morning Report: Non-Small Cell Lung Cancer | 3/3/2009 |
| MSKCC Best of ASCO – Thoracic Malignancies | 8/14/2009 |
| MSKCC Board Review Course – Thymoma and Metastatic NSCLC | 10/16/2009 |
| Landmark Clinical Trials Journal Club – Medical Oncology Fellows | 11/2/2009 |
| MSKCC Resident Noon Conference: Non-Small Cell Lung Cancer | 3/18/2010 |
| MSKCC Resident Morning Report: Non-Small Cell Lung Cancer | 10/20/2010 |
| MSKCC Resident Noon Conference: Non-Small Cell Lung Cancer | 9/20/2010 |
| MSKCC Board Review Course – Metastatic NSCLC | 9/10/2010 |
| MSKCC Resident Noon Conference: Non-Small Cell Lung Cancer | 8/4/2011 |
| Lecture: Solid Tumor/Hematologic Oncology Grand Rounds, “Targeted Therapies in Lung Adenocarcinoma: Beyond EGFR” | 10/25/2011 |
| MSKCC Board Review Course – Metastatic NSCLC | 11/4/2011 |
| Post-Treatment Resource Program Lecture: “Subtyping NSCLC” | 11/8/2011 |
| WCMC Problem Based Learning | 4/27/12-6/15/12 |
| MSKCC Resident Noon Conference: Non-Small Cell Lung Cancer | 10/16/2012 |
| Lecture: MSKCC medical oncology/hematology fellowship | 11/9/2012 |
| Lecture: Solid Tumor/Hematologic Oncology Grand Rounds, “Targeting KRAS mutant lung cancers” | 3/19/13 |
| MSKCC Board Review Course: Small Cell Lung Cancer | 3/2/2013 |
| Lecture: Radiation Oncology Residents: Treating Lung Cancer | 11/5/2013 |
| Lecture: Medical Oncology Fellows: Treatment of Advanced Lung Cancer | 11/19/2013 |
| Lecture: MSKCC Medical Oncology/Hematology Fellowship, Metastatic Non-Small Cell Lung Cancer | 2/6/2014 |
| Lecture: MSKCC K30 Reporting of Adverse Events | 10/24/2014 |
| Lecture: Radiation Oncology Residents: Systemic Therapy of Non- Small Cell Lung Cancer | 12/16/2014 |
| Lecture: MSKCC Medical Oncology/Hematology Fellowship, Metastatic Non-Small Cell Lung Cancer | 1/27/2015 |
| Lecture: Best of ASCO – Thoracic | 7/17/15 |
| Surgery Research Methods Lecture Series: Trial Design for Phase I, II, and III Trials | 8/3/15 |
| Lecture: MSKCC Medical Oncology/Hematology Fellowship, Metastatic Non-Small Cell Lung Cancer Part I | 10/27/2015 |
| Case Conference: MSKCC Medical Oncology Fellows | 11/2/15 |
| Lecture: Tumor Genomics, Targeted Therapies and Immunotherapy: What's new in Thymic Malignancies?, 2 nd Annual Advances in Thoracic Surgical Oncology, MSKCC Thoracic Surgery | 10/2/15 |
| Lecture: Treating Lung Cancer in the Molecular Era, Defining the Actionable Genome, MSK Cancer Alliance | 10/6/15 |

- Lecture: Non-Small Cell Lung Cancer at 4th Annual MSKCC Board 3/4/16
 Review Course:
2. Clinical Care (duties, dates)

| | |
|--|----------------|
| Attending Physician on the Thoracic Oncology Service, Clinic 2 days per week, Service Attending 4 weeks per year. | 1/2007-present |
|--|----------------|

 3. Administrative duties, including committees, dates

| | |
|---|----------------|
| Chief Fellow, Department of Medicine, | 6/2004-6/2005 |
| Quality Assurance Committee, Department of Medicine | 6/2004-6/2005 |
| Director, Inpatient Thoracic Oncology Service | 7/2008-5/2013 |
| Associate Chair, Clinical Trials Office, Department of Medicine | 10/2012-1/2013 |
| Vice Chair, Clinical Trials Office, Department of Medicine | 1/2013-present |

 4. Research

Clinical research focused on the development of treatments for thoracic malignancies. Specific areas of interest include non-small cell lung cancer with acquired resistance to erlotinib and gefitinib, non-small cell lung cancer with KRAS mutations, non-small cell lung cancer with ALK rearrangements (treatments and understanding acquired resistance) and management of thymic malignancies.

Clinical Trials:

- | | |
|---|--------------------------|
| Salirasib for Treatment of Advanced Non-Small Cell Lung Cancer: A Phase II Study #07-110, Role – Principal Investigator | 8/29/2007- 4/13/2010 |
| A Phase 1 Study of IPI-504 and Docetaxel in Patients with Advanced Solid Tumors #07-154, Role – Principal Investigator | 12/14/2007- 6/12/2012 |
| A Phase I/II Trial of Cetuximab in Patients with Lung Adenocarcinoma Receiving Erlotinib that have Developed "Acquired Resistance" to Erlotinib #08-055, Role – Principal Investigator | 7/15/2008 – 5/24/2011 |
| A Randomized Discontinuation Trial of Ridaforolimus in Patients with Non-Small Cell Lung Cancer and KRAS Mutations #09-047, Role – Principal Investigator | 9/15/2009 – present |
| A8081007 Phase 3, Randomized Open-Label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus #10-008, Role – Site Principal Investigator | 5/19/2010 – present |

| | |
|--|----------------------|
| A8081005 Phase 2, Open Label Single Arm Study of the Efficacy and Safety of PF-02341066 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus #10-009, Role – Site Principal Investigator | 4/27/2010 – present |
| Phase II Clinical Trial of MEK 1/2 Inhibitor AZD6244 in Cancers with BRAF Mutations Identified by Prospective Genotypic Analysis (NCI #8281) #10-010, Role – Site Principal Investigator | 6/30/2010 – present |
| Multicenter Phase II Study of IMC-A12 in Patients with Thymoma and Thymic Carcinoma who have been Previously Treated with Chemotherapy (NCI #8347) #10-207 Role – Site Principal Investigator | 2/24/2011 – present |
| Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus #11-014 Role – Site Principal Investigator | 2/8/2011 – present |
| A Phase I/II Trial of HSP90 Inhibitor AUY-922 in Patients with Lung Adenocarcinoma with "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors #11-015 Role – Principal Investigator | 7/11/2011 – present |
| A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects with Advanced Non-small Cell Lung Cancer and BRAF Mutations #11-023 Role – Site Principal Investigator | 2/9/2012 – present |
| A Phase I, Multicenter, Open-label Dose Escalation Study of LDK378, Administered Orally in Adult Patients with Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK) #11-055 Role – Site Principal Investigator | 1/10/2012 – present |
| A Phase 1b/2 Study of IPI-504 in Combination with Everolimus in Patients with KRAS Mutant NSCLC #11-114 Role – Site Principal Investigator | 11/11/2011 – present |
| A Phase I/II Study of Crizotinib and STA-9090 in ALK Positive Lung Cancers #12-015 Role – Principal Investigator | 4/16/2012 – present |
| A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and | 4/24/2012 – |

Docetaxel in Previously Treated Patients with Stage IIIB or IV Non-Small Cell Lung Cancer #12-028 Role – Principal Investigator present

A Phase II Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Non-Small Cell Lung Cancer #12-070 Role – Site Principal Investigator 5/22/2012 – present

A Phase I/II Study of the ALK Inhibitor CH5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer #12-113 Role – Site Principal Investigator 5/22/2012 – present

A Phase 2 Trial of Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those with KRAS G12D #12-222 – Principal Investigator 10/23/2012 – present

Detecting EGFR T790M Mutations from Circulating Tumor Cells #13-001 – Site Principal Investigator 4/4/13 – present

A Phase I/II, Multicenter, Open-Label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients with EGFRmut Solid Malignancies #14-112 – Site Principal Investigator 7/23/14 – present

Phase 1/2 Study of PF-06463922 (an ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations #15-132 – Site Principal Investigator 8/27/15– present

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer Pending

| | <u>Current Percent Effort (%)</u> | <u>Does the activity involve WMC students or researchers? (Y/N)</u> | <u>Does the activity involve MSK trainees or researchers? (Y/N)</u> |
|--------------------|-----------------------------------|---|---|
| Teaching/Mentoring | <u>5</u> % | Y | Y |
| Clinical Care | <u>25</u> % | Y | Y |
| Administration | <u>25</u> % | N | N |
| Research | <u>45</u> % | Y | Y |
| | TOTAL: 100% | | |

J. RESEARCH SUPPORT

CURRENT:

2R01CA121210 Pao/Lovly (PI) 5/15/12-Present
Overcoming Acquired Resistance to EGFR Inhibitors in Lung Cancer
Role: Co-Investigator, 5% T/E
This grant tests identifies preclinical and clinical mechanisms of acquired resistance to first generation EGFR TKI and clinically evaluates approaches to overcome resistance.

IRB#16-447
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer
Role: Site PI, 5% T/E
A first-in-human trial of an EGFR and HER2 inhibitor for patients with EGFR exon 20 insertions and HER2 mutant lung cancer.

IRB#15-132
Phase 1/2 Study of PF-06463922 (an ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations
Role: Site PI, 5% T/E
A first-in-human trial of an ALK And ROS1 inhibitor for patients with ALK positive or ROS1 positive lung cancer.

(b) (4)



IRB 12-222 Riely (PI) 10/23/12-Present
A Phase 2 Trial of Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those with KRAS G12D
Role: PI, 5% T/E
Investigator-initiated trial of bortezomib in patients with lung cancer with KRAS mutations, based upon correlative observations at MSKCC for patients treated on other Phase I and II trials.

(b) (4)



(b) (4)

(b) (4)

(b) (4)

(b) (4)

COMPLETED:

(b) (4)

(b) (4)

TIMRF

Riely (PI)

1/1/12-12/31/12

A Phase I/II Study of Crizotinib and STA-9090 in ALK Positive Lung Cancers

Role: PI, 5% T/E

Provided initial funding for IRB #12-115, combining an ALK inhibitor and an hsp90 inhibitor, to capitalize on pre-clinical and clinical observations of activity of hsp90 inhibitors in this setting.

(b) (4)



3U01 CA062490-16S1

Lawrence (PI)

6/30/10-11/22/11

Phase II Clinical Trial of MEK 1/2 Inhibitor AZD6244 in Cancers with BRAF Mutations

Identified by Prospective Genotypic Analysis

Role: Co-Investigator (Site PI for study)

This ARRA-funded grant explored the usage of a MEK inhibitor in patients with non-melanoma cancers with BRAF mutations.

(b) (4)



(b) (4)



(b) (4)



(b) (4)



Lung Cancer – *Ad Hoc* Reviewer
Journal of Thoracic Oncology – *Ad Hoc* Reviewer
Oncology – *Ad Hoc* Reviewer
Cancer Chemotherapy and Pharmacology– *Ad Hoc* Reviewer
The Oncologist– *Ad Hoc* Reviewer
Cancer – *Ad Hoc* Reviewer
American Journal of Clinical Oncology – *Ad Hoc* Reviewer
Journal of Clinical Oncology – *Ad Hoc* Reviewer
The Lancet – *Ad Hoc* Reviewer
New England Journal of Medicine – *Ad Hoc* Reviewer

Invited Lectures:

VEGF Trap, Cambridge Conference on Novel Agents in the Treatment of Lung Cancer, 9/29/2006
Thoracic Malignancies, Best of ASCO 2007, American Society of Clinical Oncology, Reston, VA, 6/23/2007
Second-Generation EGFR Inhibitors, Cambridge Conference on Novel Agents in the Treatment of Lung Cancer, 10/1/2007
Biomarkers in Lung Cancer, NY Biotechnology Association, New York, 5/19/2008
EGFR Targeted Therapies in Cancer: Predictors of Sensitivity and Resistance, Yonsei Cancer Research Institute, Seoul, Korea, 9/26/08
Clinical Trials in Advanced Thymoma, Thymic Malignancies Workshop, MD Anderson Cancer Center Houston, 10/3/08
Salirasib in Advanced Non-Small Cell Lung Cancer, International Association for the Study of Lung Cancer: 9th Annual Targeted Therapies of the Treatment of Lung Cancer, San Diego, 2/19/09
Multimodality Induction Therapy for Thymoma, International Conference on Thymic Malignancies, National Cancer Institute, Bethesda, 8/21/09
Advances in the Treatment of Lung Cancer, Association of Physician Assistants in Oncology National Meeting, Boston, 9/10/2009
Targeting BRAF Mutations, International Association for the Study of Lung Cancer: 10th Annual Targeted Therapies of the Treatment of Lung Cancer, San Diego, 2/26/10
AUY922 in Non-Small Cell Lung Cancer, International Association for the Study of Lung Cancer: 10th Annual Targeted Therapies of the Treatment of Lung Cancer, San Diego, 2/26/10
Acquired Resistance to Erlotinib, International Association for the Study of Lung Cancer: 10th Annual Targeted Therapies of the Treatment of Lung Cancer, San Diego, 2/26/10
EGFR and KRAS mutant Non-Small Cell Lung Cancer, Vanderbilt University Medical Center, Nashville, July 26, 2010
KRAS mutant Non-Small Cell Lung Cancer, Massachusetts General Hospital, Boston, 9/17/2010
Targeted Therapies in Lung Adenocarcinoma, Hematology/Oncology Grand Rounds, Columbia University Medical Center, New York, 2/17/2011
Vemurafenib in Non-Small Cell Lung Cancer, International Association for the Study of Lung Cancer: 11th Annual Targeted Therapies of the Treatment of Lung Cancer, San Diego, 2/25/11
AUY922 in Non-Small Cell Lung Cancer, International Association for the Study of Lung Cancer: 11th Annual Targeted Therapies of the Treatment of Lung Cancer, San Diego, 2/27/11
Preoperative Treatment of Locally Advanced Thymoma, IASLC: World Congress on Lung Cancer, Amsterdam, 7/4/2011

BRAF Inhibitors in Lung and Colorectal Adenocarcinomas, International Association for the Study of Lung Cancer: 12th Annual Targeted Therapies of the Treatment of Lung Cancer, San Diego, 2/23/12

Hsp90 inhibitor AUY922 Lung Cancer, International Association for the Study of Lung Cancer: 12th Annual Targeted Therapies of the Treatment of Lung Cancer, San Diego, 2/25/12

Educational Session: Management of Thymic Carcinoma, 2012 American Society of Clinical Oncology Annual Meeting, Chicago, 6/2/2012

Clinical Science Symposium Discussion: ROS1 Lung Adenocarcinoma, 2012 American Society of Clinical Oncology Annual Meeting, Chicago, 6/2/2012

Treatment of KRAS-mutant Non-Small Cell Lung Cancer, 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology (ASCO/ASTRO/IASLC/University of Chicago), Chicago, 9/6/2012

Recent Advances in Conventional Chemotherapy for Lung Cancer, St. Francis Hospital Cancer Day, Poughkeepsie, New York, 11/7/2013

Ridafarolimus in KRAS mutant Lung Cancers, Chemotherapy Foundation Symposium 2013, New York, 11/9/2013

Novel Targets in NSCLC, 2013 University of Washington Thoracic Oncology Symposium, Seattle, 2/1/2013

Role of Systemic Therapy for Thymoma and Thymic Carcinomas, 2013 University of Washington Thoracic Oncology Symposium, Seattle, 2/1/2013

Dabrafenib in Lung Adenocarcinomas, International Association for the Study of Lung Cancer: 13th Annual Targeted Therapies of the Treatment of Lung Cancer, San Diego, 2/21/2013

AUY922 in Lung Cancer, International Association for the Study of Lung Cancer: 13th Annual Targeted Therapies of the Treatment of Lung Cancer, San Diego, 2/21/2013

Ridafarolimus in KRAS mutant Lung Cancers, International Association for the Study of Lung Cancer: 13th Annual Targeted Therapies of the Treatment of Lung Cancer, San Diego, 2/21/2013

Role of ALK in Advanced NSCLC, Asia Pacific Oncology Summit, Hong Kong, 4/13/2013

Treatment of KRAS Mutant Lung Cancers, 6th International Conference on Molecular Targeted Therapy in Lung Cancer, Sorrento, Italy, 4/18/2013

Adjuvant Treatment of Resected Stage I-IIIa with a Sensitizing Mutation in EGFR, American Thoracic Society 2013 International Conference, Philadelphia, 5/19/2013

Non-small Cell Lung Cancer, American Society of Clinical Oncology 2013 Best of ASCO Boston, Boston, 8/24/2013

The New Adenocarcinoma Classification Explained, 15th World Conference on Lung Cancer, Sydney, 10/29/2013

Targeting KRAS and KRAS Signaling in the Clinic, 15th World Conference on Lung Cancer, Sydney, 10/30/2013

Ridafarolimus in KRAS mutant Lung Cancers, International Association for the Study of Lung Cancer: 14th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, 2/19/2014

Ganetespib and Crizotinib in ALK Positive Lung Cancers, International Association for the Study of Lung Cancer: 14th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, 2/19/2014

Moving Beyond Chemotherapy for Thymic Tumors and Mesothelioma, 2014 American Society of Clinical Oncology Annual Meeting, Chicago, 6/1/2014

Thymic Malignancies, Multi-disciplinary Thoracic Oncology: State-of-the-art, Columbia Presbyterian Medical Center, New York, 6/13/14

Best of ASCO Lung, Nebraska Oncology Society, Dr. Peter Townley Midwest Regional ASCO Review, June 21, 2014

Studying Rare Diseases and Acquired Resistance, Food and Drug Administration, Silver Spring, Maryland, September 15, 2014.

Targeting KRAS mutant non-small cell lung cancer, MD Anderson Cancer Center, Houston, September 18, 2014.

Management of Thoracic Malignancies, Austria American Foundation/Open Medical Institute, Salzburg, December 8-12, 2014.

Targeting Oncogenes, Winship Cancer Center Grand Rounds at Emory University, Atlanta, February 11, 2105.

EGF816, International Association for the Study of Lung Cancer: 15th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, February 19, 2015.

Temsirolimus, International Association for the Study of Lung Cancer: 15th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, February 20, 2015.

Ridaforolimus, International Association for the Study of Lung Cancer: 15th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, February 20, 2015.

Targeted Therapy for EGFR and KRAS mutant Lung Cancer, Center for Cancer Targeted Therapies, Vanderbilt University, Nashville, April 29, 2015

Targeting the Target in Non-Small Cell Lung Cancer and Squamous Cell Carcinoma, Discussion, 2015 American Society of Clinical Oncology Annual Meeting, Chicago, May 29, 2015

Beyond Second-Line Therapy, 2015 American Society of Clinical Oncology Annual Meeting, Chicago, May 29, 2015

Best of ASCO Lung, Nebraska Oncology Society, Dr. Peter Townley Midwest Regional ASCO Review, Omaha, June 20, 2015

Blueprint 2020: Clinical Trial Designs, Food and Drug Administration, Silver Spring, July 24, 2015

Non-Small Cell Lung Cancer 2015, South Carolina Oncology Society, Charleston, August 8, 2015

Multimodality Care of the Patient with Early Stage Lung Cancer, Association of Physician Assistants in Oncology Annual Meeting, Alexandria, Virginia, September 19, 2015

Beyond EGFR and ALK, Chemotherapy Foundation Symposium 2015, New York, 11/6/2015

EGF816, International Association for the Study of Lung Cancer: 16th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, February 18, 2016.

Precision Medicine for Lung Cancer, American Cancer Society Cancer Action Network, New York, June 1, 2016.

L. **BIBLIOGRAPHY**

1. Articles in professional peer-reviewed journals
 1. Villa-Garcia M, Li L, **Riely G**, Bray PF. Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene. *Blood*. 1994;83(3):668-676. PMID: 8298129.
 2. Rachmilewitz J, **Riely GJ**, Tykocinski ML. Placental protein 14 functions as a direct T-cell inhibitor. *Cell Immunol*. 1999;191(1):26-33. PMID: 9918684.

3. **Riely GJ**, Rachmilewitz J, Koo PH, Tykocinski ML. alpha2-macroglobulin modulates the immunoregulatory function of the lipocalin placental protein 14. *Biochem J.* 2000;351 Pt 2:503-508. PMCID: 1221387. PMID: 11023837.
4. Rachmilewitz J, **Riely GJ**, Huang JH, Chen A, Tykocinski ML. A rheostatic mechanism for T-cell inhibition based on elevation of activation thresholds. *Blood.* 2001;98(13):3727-3732. PMID: 11739178.
5. Rachmilewitz J, Borovsky Z, Mishan-Eisenberg G, Yaniv E, **Riely GJ**, Tykocinski ML. Focal localization of placental protein 14 toward sites of TCR engagement. *J Immunol.* 2002;168(6):2745-2750. PMID: 11884441.
6. Rachmilewitz J, Borovsky Z, **Riely GJ**, Miller R, Tykocinski ML. Negative regulation of T cell activation by placental protein 14 is mediated by the tyrosine phosphatase receptor CD45. *J Biol Chem.* 2003;278(16):14059-14065. PMID: 12556471.
7. Pao W, Miller VA, Politi KA, **Riely GJ**, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med.* 2005;2(3):e73. PMCID: 549606. PMID: 15737014.
8. Pao W, Wang TY, **Riely GJ**, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med.* 2005;2(1):e17. PMCID: 545207. PMID: 15696205.
9. Balak MN, Gong Y, **Riely GJ**, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. *Clin Cancer Res.* 2006;12(21):6494-6501. PMID: 17085664.
10. Milton DT, **Riely GJ**, Pao W, Miller VA, Kris MG, Heelan RT. Molecular on/off switch. *J Clin Oncol.* 2006;24(30):4940-4942. PMID: 17050880.
11. Pham D, Kris MG, **Riely GJ**, Sarkaria IS, McDonough T, Chuai S, Venkatraman ES, Miller VA, Ladanyi M, Pao W, Wilson RK, Singh B, Rusch VW. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. *J Clin Oncol.* 2006;24(11):1700-1704. PMID: 16505411.
12. **Riely GJ**, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. *Clin Cancer Res.* 2006;12(3 Pt 1):839-844. PMID: 16467097.
13. Bean J, Brennan C, Shih JY, **Riely G**, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proc Natl Acad Sci U S A.* 2007;104(52):20932-20937. PMCID: 2409244. PMID: 18093943.
14. Milton DT, **Riely GJ**, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. *Cancer.* 2007;110(3):599-605. PMID: 17577220.

15. **Riely GJ**, Gadgeel S, Rothman I, Saidman B, Sabbath K, Feit K, Kris MG, Rizvi NA. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. *Lung Cancer*. 2007;55(2):181-185. PMID: 17092603.
16. **Riely GJ**, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH, Miller VA. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. *Clin Cancer Res*. 2007;13(17):5150-5155. PMID: 17785570.
17. Bean J, **Riely GJ**, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. *Clin Cancer Res*. 2008;14(22):7519-7525. PMCID: 2596620. PMID: 19010870.
18. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, **Riely GJ**, Yeap BY, Halmos B, Kim JH, Janne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. *Clin Cancer Res*. 2008;14(21):7060-7067. PMCID: 2596582. PMID: 18981003.
19. Li AR, Chitale D, **Riely GJ**, Pao W, Miller VA, Zakowski MF, Rusch V, Kris MG, Ladanyi M. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. *J Mol Diagn*. 2008;10(3):242-248. PMCID: 2329789. PMID: 18403609.
20. Marks JL, Golas B, Kirchoff T, Miller VA, **Riely GJ**, Offit K, Pao W. EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. *J Thorac Oncol*. 2008;3(7):805. PMID: 18594331.
21. Miller VA, **Riely GJ**, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. *J Clin Oncol*. 2008;26(9):1472-1478. PMID: 18349398.
22. Motoi N, Szoke J, **Riely GJ**, Seshan VE, Kris MG, Rusch VW, Gerald WL, Travis WD. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. *Am J Surg Pathol*. 2008;32(6):810-827. PMID: 18391747.
23. **Riely GJ**, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. *Clin Cancer Res*. 2008;14(18):5731-5734. PMCID: 2754127. PMID: 18794081.
24. Rizvi NA, **Riely GJ**, Azzoli CG, Miller VA, Ng KK, Fiore J, Chia G, Brower M, Heelan R, Hawkins MJ, Kris MG. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. *J Clin Oncol*. 2008;26(4):639-643. PMID: 18235124.
25. Girard N, Shen R, Guo T, Zakowski MF, Heguy A, **Riely GJ**, Huang J, Lau C, Lash AE, Ladanyi M, Viale A, Antonescu CR, Travis WD, Rusch VW, Kris MG, Pao W. Comprehensive

genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. *Clin Cancer Res.* 2009;15(22):6790-6799. PMID: 19861435. PMCID: 2783876.

26. Huang J, Rizk NP, Travis WD, **Riely GJ**, Park BJ, Bains MS, Dycoco J, Flores RM, Downey RJ, Rusch VW. Comparison of patterns of relapse in thymic carcinoma and thymoma. *J Thorac Cardiovasc Surg.* 2009;138(1):26-31. PMID: 19577051.

27. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Janne PA, **Riely GJ**, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. *Clin Cancer Res.* 2009;15(16):5267-5273. PMID: 19671843. PMCID: 3219530.

28. **Riely GJ**, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Sirotnak FM, Seshan VE, Fogle M, Ginsberg M, Miller VA, Rudin CM. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. *J Clin Oncol.* 2009;27(2):264-270. PMID: 2645610. PMCID: 19047285.

29. Zhao B, James LP, Moskowitz CS, Guo P, Ginsberg MS, Lefkowitz RA, Qin Y, **Riely GJ**, Kris MG, Schwartz LH. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. *Radiology.* 2009;252(1):263-272. PMID: 2797680. PMCID: 19561260.

30. Girard N, Lou E, Azzoli CG, Reddy R, Robson M, Harlan M, Orlov I, Yatabe Y, Nafa K, Ladanyi M, Viale A, Kris MG, **Riely G**, Miller V, Klein RJ, Matsuo K, Pao W. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. *Clin Cancer Res.* 2010;16(2):755-763. PMID: 20068085. PMCID: 2808124.

31. Girard N, Teruya-Feldstein J, Payabyab EC, **Riely GJ**, Rusch VW, Kris MG, Zakowski MF. Insulin-like growth factor-1 receptor expression in thymic malignancies. *J Thorac Oncol.* 2010;5(9):1439-1446. PMID: 20736806.

32. Janjigian YY, McDonnell K, Kris MG, Shen R, Sima CS, Bach PB, Rizvi NA, **Riely GJ**. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. *Cancer.* 2010;116(3):670-675. PMID: 20029977. PMCID: 2815173.

33. Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, **Riely GJ**, Heelan RT, Arcila ME, Miller VA. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. *J Thorac Oncol.* 2010;5(10):1623-1629. PMID: 20871262.

34. Yeo WL, **Riely GJ**, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. *J Thorac Oncol.* 2010;5(7):1048-1053. PMID: 20512075. PMCID: 2893286.

35. Arcila ME, Oxnard GR, Nafa K, **Riely GJ**, Solomon SB, Zakowski MF, Kris MG, Pao W, Miller VA, Ladanyi M. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. *Clin Cancer Res.* 2011;17(5):1169-1180. PMID: 21248300. PMCID: 3070951.

36. Bott MJ, Wang H, Travis W, **Riely GJ**, Bains M, Downey R, Rusch V, Huang J. Management and outcomes of relapse after treatment for thymoma and thymic carcinoma. *Ann Thorac Surg*. 2011;92(6):1984-1991; PMID: 22115206.
37. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, **Riely GJ**. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. *Clin Cancer Res*. 2011;17(19):6298-6303. PMID: 21856766.
38. D'Angelo SP, Pietanza MC, Johnson ML, **Riely GJ**, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. *J Clin Oncol*. 2011;29(15):2066-2070. PMCID: 3296671. PMID: 21482987.
39. Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA, **Riely GJ**. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. *Clin Cancer Res*. 2011;17(8):2521-2527. PMID: 21248303.
40. Johnson ML, **Riely GJ**, Rizvi NA, Azzoli CG, Kris MG, Sima CS, Ginsberg MS, Pao W, Miller VA. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. *J Thorac Oncol*. 2011;6(6):1128-1131. PMCID: 3230574. PMID: 21623279.
41. Oxnard GR, Arcila ME, Sima CS, **Riely GJ**, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. *Clin Cancer Res*. 2011;17(6):1616-1622. PMCID: 3060283. PMID: 21135146.
42. Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, **Riely GJ**, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. *Clin Cancer Res*. 2011;17(19):6322-6328. PMCID: 3186869. PMID: 21831955.
43. Oxnard GR, Zhao B, Sima CS, Ginsberg MS, James LP, Lefkowitz RA, Guo P, Kris MG, Schwartz LH, **Riely GJ**. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. *J Clin Oncol*. 2011;29(23):3114-3119. PMCID: 3157977. PMID: 21730273.
44. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, **Riely GJ**. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. *J Clin Oncol*. 2011;29(15):2046-2051. PMCID: 3107760. PMID: 21483012.
45. Paik PK, James LP, **Riely GJ**, Azzoli CG, Miller VA, Ng KK, Sima CS, Heelan RT, Kris MG, Moore E, Rizvi NA. A phase 2 study of weekly albumin-bound paclitaxel (Abraxane(R)) given as a two-hour infusion. *Cancer Chemother Pharmacol*. 2011;68(5):1331-1337. PMID: 21461889.
46. Reinersman JM, Johnson ML, **Riely GJ**, Chitale DA, Nicastri AD, Soff GA, Schwartz AG, Sima CS, Ayalew G, Lau C, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. *J Thorac Oncol*. 2011;6(1):28-31. PMCID: 3337520. PMID: 21107288.

47. Rekhtman N, Brandt SM, Sigel CS, Friedlander MA, **Riely GJ**, Travis WD, Zakowski MF, Moreira AL. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. *J Thorac Oncol.* 2011;6(3):451-458. PMID: 21266922.
48. **Riely GJ**, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W, Ginsberg MS. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. *J Thorac Oncol.* 2011;6(8):1435-1437. PMID: 21847063.
49. Shaw AT, Yeap BY, Solomon BJ, **Riely GJ**, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol.* 2011;12(11):1004-1012. PMCID: 3328296. PMID: 21933749.
50. Sigel CS, Moreira AL, Travis WD, Zakowski MF, Thornton RH, **Riely GJ**, Rekhtman N. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. *J Thorac Oncol.* 2011;6(11):1849-1856. PMID: 21841504.
51. Yoshizawa A, Motoi N, **Riely GJ**, Sima CS, Gerald WL, Kris MG, Park BJ, Rusch VW, Travis WD. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. *Mod Pathol.* 2011;24(5):653-664. PMID: 21252858.
52. Chaft JE, Arcila ME, Paik PK, Lau C, **Riely GJ**, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M, Kris MG. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. *Mol Cancer Ther.* 2012;11(2):485-491. PMID: 22135231.
53. Chaft JE, Rekhtman N, Ladanyi M, **Riely GJ**. ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. *J Thorac Oncol.* 2012;7(4):768-769. PMID: 22425930.
54. Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, **Riely G**, Pao W. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. *Eur Respir J.* 2012;39(2):366-372. PMID: 21778168.
55. Kadota K, Suzuki K, Kachala SS, Zabor EC, Sima CS, Moreira AL, Yoshizawa A, **Riely GJ**, Rusch VW, Adusumilli PS, Travis WD. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. *Mod Pathol.* 2012 Aug;25(8):1117-27. PMID: 22499226.
56. Paik PK, Johnson ML, D'Angelo SP, Sima CS, Ang D, Dogan S, Miller VA, Ladanyi M, Kris MG, **Riely GJ**. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. *Cancer.* 2012 Dec 1;118(23):5840-7. PMID: 22605530.
57. Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM Jr, Wertheim MS, Price KA, **Riely GJ**, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, Mitchell B, Rizvi NA. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. *J Thorac Oncol.* 2012 May;7(5):856-65.
58. Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Chan TA, Rizvi NA, Azzoli CG, **Riely GJ**, Kris MG, Krug LM. Phase II

trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. *Clin Cancer Res.* 2012;18(4):1138-1145. PMID: 22228633.

59. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, **Riely GJ**, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. *Proc Natl Acad Sci U S A.* 2012 Jul 31;109(31):E2127-33.

60. Johnson ML, Sima CS, Chaft J, Paik PK, Pao W, Kris MG, Ladanyi M, **Riely GJ**. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. *Cancer.* 2013 Jan 15;119(2):356-62.

61. Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, Awad MM, Engelman JA, **Riely GJ**, Monica V, Yeap BY, Scagliotti GV. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. *Ann Oncol.* 2013 Jan;24(1):59-66.

62. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, **Riely GJ**, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncol.* 2012 Oct;13(10):1011-9.

63. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, **Riely GJ**, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation. *Cancer Discov.* 2012 Oct;2(10):922-933

64. Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, **Riely GJ**, Kris MG, Zakowski MF, Ladanyi M. Molecular Epidemiology of EGFR and KRAS Mutations in 3026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-related KRAS-mutant Cancers. *Clin Cancer Res.* 2012 Nov 15;18(22):6169-77

65. D'Angelo SP, Janjigian YY, Ahye N, **Riely GJ**, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. *J Thorac Oncol.* 2012 Dec;7(12):1815-22.

66. Varghese AM, Sima CS, Chaft JE, Johnson ML, **Riely GJ**, Ladanyi M, Kris MG. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. *J Thorac Oncol.* 2013 Jan;8(1):123-5.

67. Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, Pietanza MC, Azzoli CG, Rizvi NA, Krug LM, Miller VA, Kris MG, **Riely GJ**. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. *J Thorac Oncol.* 2013 Mar;8(3):346-51.

68. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, **Riely GJ**. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-

TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. *Clin Cancer Res.* 2013 Apr 15;19(8):2240-7.

69. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, **Riely GJ**, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA Jr, Pao W. Characteristics of Lung Cancers Harboring NRAS Mutations. *Clin Cancer Res.* 2013 May 1;19(9):2584-2591

70. Rekhtman N, Ang DC, **Riely GJ**, Ladanyi M, Moreira AL. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. *Mod Pathol.* 2013 Oct;26(10):1307-19.

71. Kim HR, Ahn JR, Lee JG, Bang DH, Ha SJ, Hong YK, Kim SM, Nam KC, Rha SY, Soo RA, **Riely GJ**, Kim JH, Cho BC. The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. *Yonsei Med J.* 2013 Jul;54(4):865-74.

72. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, **Riely GJ**, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med.* 2013 Jun 20;368(25):2385-94.

73. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, **Riely GJ**, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer. *Clin Cancer Res.* 2013 Aug 1;19(15):4273-81.

74. Hellmann MD, Chaft JE, Rusch V, Ginsberg MS, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, **Riely GJ**, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA, Paik PK. Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. *Cancer Chemother Pharmacol.* 2013 Aug;72(2):453-61.

75. Chaft JE, Rusch V, Ginsberg MS, Paik PK, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, **Riely GJ**, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA. Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non-Small-Cell Lung Cancers. *J Thorac Oncol.* 2013 Aug;8(8):1084-90.

76. Rekhtman N, Borsu L, Reva B, Arcila M, **Riely GJ**, Ladanyi M, Drilon A. Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles. *J Thorac Oncol.* 2014 Jan;9(1):e1-3.

77. Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, **Riely GJ**, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. *Sci Transl Med.* 2013 Dec 18;5(216):216

78. Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, **Riely GJ**, Giaccone G. Cixutumumab for patients with recurrent or refractory advanced

thymic epithelial tumours: a multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2014 Feb;15(2):191-200.

79. Kadota K, Villena-Vargas J, Yoshizawa A, Motoi N, Sima CS, **Riely GJ**, Rusch VW, Adusumilli PS, Travis WD. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. *Am J Surg Pathol.* 2014 Apr;38(4):448-60.

80. Ou SH, Jänne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, Crinò L, Selaru P, Cohen DP, Clark JW, **Riely GJ**. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. *Ann Oncol.* 2014 Feb;25(2):415-22.

81. Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, **Riely GJ**. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. *Ann Oncol.* 2014 Feb;25(2):423-8.

82. Rimner A, Gomez DR, Wu AJ, Shi W, Yorke ED, Moreira AL, Rice D, Komaki R, Rosenzweig KE, **Riely GJ**, Huang J. Failure patterns relative to radiation treatment fields for stage II-IV thymoma. *J Thorac Oncol.* 2014 Mar;9(3):403-9.

83. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, **Riely GJ**, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med.* 2014 Mar 27;370(13):1189-97.

84. Gerber NK, Yamada Y, Rimner A, Shi W, **Riely GJ**, Beal K, Yu HA, Chan TA, Zhang Z, Wu AJ. Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma. *Int J Radiat Oncol Biol Phys.* 2014 Jun 1;89(2):322-9.

85. Yu HA, Arcila ME, Harlan Fleischut M, Stadler Z, Ladanyi M, Berger MF, Robson M, **Riely GJ**. Germline EGFR T790M mutation found in multiple members of a familial cohort. *J Thorac Oncol.* 2014 Apr;9(4):554-8. PMID: 24736080

86. Varghese AM, Zakowski MF, Yu HA, Won HH, **Riely GJ**, Krug LM, Kris MG, Rekhman N, Ladanyi M, Wang L, Berger MF, Pietanza MC. Small-cell lung cancers in patients who never smoked cigarettes. *J Thorac Oncol.* 2014 Jun;9(6):892-6. PMID: 24828667

87. Kadota K, Yeh YC, D'Angelo SP, Moreira AL, Kuk D, Sima CS, **Riely GJ**, Arcila ME, Kris MG, Rusch VW, Adusumilli PS, Travis WD. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. *Am J Surg Pathol.* 2014 Aug;38(8):1118-27. PMID: 25029118

88. Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, **Riely GJ**, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations. *Cancer Discov.* 2014 Sep;4(9):1036-45. PMID: 25074459

89. Gadgeel SM, Gandhi L, **Riely GJ**, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. *Lancet Oncol.* 2014 Sep;15(10):1119-28. PMID: 25153538

90. Zauderer MG, Drilon A, Kadota K, Huberman K, Sima CS, Bergagnini I, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, **Riely GJ**, Kris MG, Krug LM, Pietanza MC. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. *Lung Cancer*. 2014 Aug 17. [Epub ahead of print] PMID: 25194640
91. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, **Riely GJ**, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer. *N Engl J Med*. 2014 Sep 27. [Epub ahead of print] PMID: 25264305
92. Moreira AL, Won HH, McMillan R, Huang J, **Riely GJ**, Ladanyi M, Berger MF. Massively Parallel Sequencing Identifies Recurrent Mutations in TP53 in Thymic Carcinoma Associated with Poor Prognosis. *J Thorac Oncol*. 2015 Feb;10(2):373-80. PMID: 25299233
93. Halpenny DF, **Riely GJ**, Hayes S, Yu H, Zheng J, Moskowitz CS, Ginsberg MS. Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements? *Lung Cancer*. 2014 Nov;86(2):190-4. PMID: 25312988
94. Litvak AM, Woo K, Hayes S, Huang J, Rimmer A, Sima CS, Moreira AL, Tsukazan M, **Riely GJ**. Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging. *J Thorac Oncol*. 2014 Dec; 9(12):1810-5. PMID: 25393794
95. Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, **Riely GJ**. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. *J Thorac Oncol*. 2014 Nov 20. PMID: 25415430
96. Litvak AM, Paik PK, Woo KM, Sima CS, Hellmann MD, Arcila ME, Ladanyi M, Rudin CM, Kris MG, **Riely GJ**. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. *J Thorac Oncol*. 2014 Nov;9(11):1669-74. PMID: 25436800
97. Costa DB, Shaw AT, Ou SH, Solomon BJ, **Riely GJ**, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crinò L. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. *J Clin Oncol*. 2015 Jan 26. pii: JCO.2014.59.0539. PMID: 25624436
98. Yu HA, Sima CS, Hellmann MD, Naidoo J, Busby N, Rodriguez K, **Riely GJ**, Kris MG. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. *Cancer*. 2015 Jun 15;121(12):2078-82. PMID: 2578186
99. Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker AW, Patel JD, Kris MG, **Riely GJ**. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. *J Clin Oncol*. 2015 May 20;33(15):1666-73.
100. Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, **Riely GJ**, Kris MG, Arcila ME, Yu HA. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. *Cancer*. 2015 Jun 10. PMID: 26096453

101. Yu HA, Tian SK, Drilon AE, Borsu L, **Riely GJ**, Arcila ME, Ladanyi M. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. *JAMA Oncol.* 2015 May 7. PMID: 26181354
102. Sundaresan TK, Sequist LV, Heymach JV, **Riely GJ**, Janne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U, Fleisher M, Yu H, Wei W, Johnson BE, Barber TA, Walsh JR, Engelman JA, Stott SL, Kapur R, Maheswaran S, Toner M, Haber DA. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. *Clin Cancer Res.* 2016 Mar 1;22(5):1103-10. PMID: 26446944
103. Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, **Riely GJ**, Druker BJ, O'Hare T, Ladanyi M, Davare MA. A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. *Clin Cancer Res.* 2015 Dec 16. PMID: 26673800
104. Shaw AT, Gandhi L, Gadgeel S, **Riely GJ**, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. *Lancet Oncol.* 2016 Feb;17(2):234-42. PMID: 26708155
105. Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, Kris MG, **Riely GJ**, Lito P, Iqbal A, Veach S, Smith-Marrone S, Sarkaria IS, Krug LM, Rudin CM, Travis WD, Rekhtman N, Pietanza MC. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. *Clin Lung Cancer.* 2016 Jan 21. PMID: 26898325
106. Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, **Riely GJ**, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. *Lancet Oncol.* 2016 Mar 10. PMID: 26973324
107. Drilon A, Bergagnini I, Delasos L, Sabari J, Woo K, Plodkowski A, Wang L, Hellmann M, Joubert P, Sima C, Smith R, Somwar R, Rekhtman N, Ladanyi M, **Riely GJ**, Kris MG. Clinical Outcomes with Pemetrexed-Based Systemic Therapies in RET-rearranged Lung Cancers. *Ann Oncol.* 2016 Apr 7. PMID: 27056998
108. Planchard D, Kim TM, Mazieres J, Quoix E, **Riely G**, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A Jr, Mookerjee B, Curtis CM Jr, Johnson BE. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2016 Apr 11. PMID: 27080216

2. Books, book chapters and reviews

1. **Riely GJ**, Pao W. Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important? *Cancer Biol Ther.* 2005;4(10):1096-1097. PMID: 16294020.
2. **Riely GJ**, Pao W, Miller VA. Selection of Patients for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. *Lung Cancer Updates.* 2005;5(1):1-8. PMID:

3. **Riely GJ**, Miller VA. Bronchioloalveolar Carcinoma. In: Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, editors. Textbook of Uncommon Cancer. West Sussex, England: John Wiley & Sons, Ltd.; 2006.
4. **Riely GJ**, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12(24):7232-7241. PMID: 17189394.
5. Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, **Riely GJ**, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS. Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res. 2007;13(15 Pt 2):s4583-4588. PMID: 17671145.
6. **Riely GJ**, Miller VA. Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res. 2007;13(15 Pt 2):s4623-4627. PMID: 17671153.
7. Garcia J, **Riely GJ**, Nafa K, Ladanyi M. KRAS mutational testing in the selection of patients for EGFR-targeted therapies. Semin Diagn Pathol. 2008;25(4):288-294. PMID: 19013894.
8. Huang J, **Riely GJ**, Rosenzweig KE, Rusch VW. Multimodality therapy for locally advanced thymomas: state of the art or investigational therapy? Ann Thorac Surg. 2008;85(2):365-367. PMID: 18222226.
9. Lynch TJ, Jr., Blumenschein GR, Jr., Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, **Riely GJ**, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol. 2008;3(6 Suppl 2):S107-112. PMID: 18520291.
10. **Riely GJ**. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Oncol. 2008;3(6 Suppl 2):S146-149. PMID: 18520300.
11. **Riely GJ**. The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. Lung Cancer. 2008;60 Suppl 2:S19-22. PMID: 18513580.
12. **Riely GJ**, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn. 2008;10(6):493-495. PMID: 18832458.
13. **Riely GJ**, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009;6(2):201-205. PMID: 19349489.
14. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Jr., Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, **Riely GJ**, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740-801. PMID: 20679538.
15. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Jr., Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, **Riely GJ**, Rohren E, Swanson SJ, Wood DE, Yang SC. Thymic malignancies. J Natl Compr Canc Netw. 2010;8(11):1302-1315. PMID: 21081786.

16. Jackman D, Pao W, **Riely GJ**, Engelman JA, Kris MG, Janne PA, Lynch T, Johnson BE, Miller VA. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *J Clin Oncol*. 2010;28(2):357-360. PMID: 19949011.
17. **Riely GJ**. Lung cancer in 'Never-smokers': molecular factors trump risk factors. *Oncology (Williston Park)*. 2010;24(1):38, 40. PMID: 20187319.
18. **Riely GJ**, Huang J. Induction therapy for locally advanced thymoma. *J Thorac Oncol*. 2010;5(10 Suppl 4):S323-326. PMID: 20859127.
19. Girard N, Lal R, Wakelee H, **Riely GJ**, Loehrer PJ. Chemotherapy definitions and policies for thymic malignancies. *J Thorac Oncol*. 2011;6(7 Suppl 3):S1749-1755. PMID: 21847058.
20. **Riely GJ**. Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitors. *J Thorac Oncol*. 2011;6(11 Suppl 4):S1803-1804. PMID: 22005537.
21. **Riely GJ**, Chaft JE, Ladanyi M, Kris MG. Incorporation of crizotinib into the NCCN guidelines. *J Natl Compr Canc Netw*. 2011;9(12):1328-1330. PMID: 22157552.
22. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, **Riely G**, Garg K, Austin JH, Rusch VW, Hirsch FR, Jett J, Yang PC, Gould M. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. *Proc Am Thorac Soc*. 2011;8(5):381-385. PMID: 21926387.
23. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, **Riely GJ**, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol*. 2011;6(2):244-285. PMID: 21252716.
24. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, **Riely GJ**, Rohren E, Swanson SJ, Wood DE, Yang SC. Malignant pleural mesothelioma. Clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. 2012;10(1):26-41. PMID: 22223867.
25. **Riely GJ**, Huang J, Rimmer A. Multidisciplinary Management of Thymic Carcinoma, ASCO 2012 Educational Book. 466-470
26. Yu HA, **Riely GJ**. Who should receive EGFR tyrosine-kinase inhibitors?, *Lancet Oncol* 2012 Nov;13(11):1074-6.
27. Yu HA, **Riely GJ**. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. *J Natl Compr Canc Netw*. 2013 Feb 1;11(2):161-9.
28. Travis WD, Brambilla E, **Riely GJ**. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. *J Clin Oncol*. 2013 Mar 10;31(8):992-1001.

29. Ettinger DS, **Riely GJ**, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M. Thymomas and thymic carcinomas. *J Natl Compr Canc Netw*. 2013 May 1;11(5):562-76.
30. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, **Riely GJ**, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 2.2013. *J Natl Compr Canc Netw*. 2013 Jun 1;11(6):645-53.
31. **Riely GJ**, Travis WD. Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma? *Eur Respir J*. 2014 May;43(5):1240-2. PMID: 24789948
32. Yu HA, **Riely GJ**, Lovly CM. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. *Clin Cancer Res*. 2014 Dec 1;20(23):5898-907. PMID: 25303979
33. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, **Riely GJ**, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 1.2015. *J Natl Compr Canc Netw*. 2014 Dec;12(12):1738-61. PMID: 25505215
34. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, **Riely GJ**, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 6.2015. *J Natl Compr Canc Netw*. 2015 May;13(5):515-24. PMID: 25964637
35. EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. **Riely GJ**, Yu HA. *Clin Cancer Res*. 2015 May 15;21(10):2221-6. doi: 10.1158/1078-0432.CCR-14-3154. PMID: 25979928
36. Beyond "second-line" in non-small cell lung cancer: therapy and supportive care. Martins RG, Reynolds CH, **Riely GJ**. *Am Soc Clin Oncol Educ Book*. 2015;35:e414-8. doi: 10.14694/EdBook_AM.2015.35.e414. PMID: 25993204
37. Riely GJ. Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutations. *Clin Adv Hematol Oncol*. 2016 Jan;14(1):41-5. PMID: 27057667
38. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J,

Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. *J Natl Compr Canc Netw*. 2016 Mar;14(3):255-64. PMID: 26957612